Skip to main content
Have a personal or library account? Click to login
Angiogenesis and Non Small Cell Lung Cancer Cover

Angiogenesis and Non Small Cell Lung Cancer

Balkan Journal of Medical Genetics
Volume 11 (2008): Issue 2 (December 2008)
By:   
Open Access
|May 2009
References

References

  1. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of nonsmall cell lung cancer: current indications and future developments.2007; 12(10): 1183-1193.
    Open DOISearch in Google Scholar
  2. Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma.2008; 36(1): 88-95.
    Open DOISearch in Google Scholar
  3. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer.2007; 13(7): 1961-1970.
    Open DOISearch in Google Scholar
  4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer.2002; 346(2): 92-98.
    Open DOISearch in Google Scholar
  5. Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer.2003; 9(2): 207-236.
    Open DOISearch in Google Scholar
  6. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.2005; 11(11): 3974-3986.
    Open DOISearch in Google Scholar
  7. Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer.2007; 18 (Suppl 9): ix135-142.
    Open DOISearch in Google Scholar
  8. Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival.2004; 112(7-8): 431-440.
    Open DOISearch in Google Scholar
  9. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer.2002; 19(3): 557-570.
    Open DOISearch in Google Scholar
  10. Pang RWC, Poon RTP. Clinical implications of angiogenesis in cancers.2006; 2(2): 97-108.
    Open DOISearch in Google Scholar
  11. Hu J, Bianchi F, Ferguson M, Cesario A, Margaritora S, Granone P, Goldstraw P, Tetlow M, Ratcliffe C, Nicholson AG, Harris A, Gatter K, Pezzella F. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.2005; 24(7): 1212-1219.
    Open DOISearch in Google Scholar
  12. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J. Patterns of angiogenesis in non-small cell lung carcinoma.2001; 91(8): 1500-1509.
    Open DOISearch in Google Scholar
  13. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.2005; 23(3): 193-200.
    Open DOISearch in Google Scholar
  14. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications.2005; 23(14): 3243-3256.
    Open DOISearch in Google Scholar
  15. Gazdar AF, Minna JD. Angiogenesis and the multistage development of lung cancers.2000; 6(5): 1611-1612.
    Search in Google Scholar
  16. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer.2007; 117(10): 2740-2750.
    Open DOISearch in Google Scholar
  17. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer.2004; 1028: 351-360.
    Open DOISearch in Google Scholar
  18. McClelland MR, Carskadon SL, Zhao L, White ES, Beer DG, Orringer MB, Pickens A, Chang AC, Arenberg DA. Diversity of the angiogenic phenotype in non-small cell lung cancer.2007; 36(3): 343-350.
    Open DOISearch in Google Scholar
  19. Lymn JS, Gallagher KL, Clunn GF, Fexby SE, Patel MK, Hughes AD. PDGF stimulates DNA synthesis in human vascular smooth muscle cells via a novel wortmannin-insensitive phosphatidylinositol 3-kinase.2003; 555(3): 591-596.
    Open DOISearch in Google Scholar
  20. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors.1994; 125(4): 917-928.
    Open DOISearch in Google Scholar
  21. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.2004; 15(4): 275-286.
    Open DOISearch in Google Scholar
  22. Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, Keren G, George J. Constitutive expression of HIF-1α and HIF-2α in bone marrow stromal cells differentially promotes their proangiogenic properties.2008; 26(10): 2634-2643.
    Open DOISearch in Google Scholar
  23. Hofmann HS, Hansen G, Richter G, Taege C, Simm A, Silber RE, Burdach S. Matrix metalloproteinase- 12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients.2005; 11(3): 1086-1092.
    Open DOISearch in Google Scholar
  24. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.1997; 62(5): 554-562.
    Open DOISearch in Google Scholar
  25. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer.2000; 162(5): 1957-1963.
    Open DOISearch in Google Scholar
  26. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer2004; 22(11): 2184-2191.
    Open DOISearch in Google Scholar
  27. Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer.2006; 4(11 Suppl 23):1-10.
    Search in Google Scholar
  28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.2006; 355(24): 2542-2550.
    Open DOISearch in Google Scholar
  29. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer—how to handle stage I disease.2007; 12(3): 331-337.
    Open DOISearch in Google Scholar
  30. Ardizzoni A, Tiseo M. Combination of target agents: challenges and opportunities.2007; 2(Suppl 5): S4-6.
    Open DOISearch in Google Scholar
  31. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.2000; 77: 25-79.
    Open DOISearch in Google Scholar
  32. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients.2003; 13(5): 289-298.
    Open DOISearch in Google Scholar
  33. Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.2008; 11(3): 99-109.
    Open DOISearch in Google Scholar
  34. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.2005; 23(11): 2544-2555.
    Open DOISearch in Google Scholar
  35. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC).2007; 25(Suppl 18): Abstract 7625.
    Open DOISearch in Google Scholar
  36. Ryan AJ, Wedge SR. ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.2005; 92(Suppl 1): S6-13.
    Open DOISearch in Google Scholar
  37. Tiseo M, Franciosi V, Ardizzoni A. Multitarget inhibitors in non-small cell lung cancer (NSCLC).2006; 17(Suppl 2): ii55-ii57.
    Open DOISearch in Google Scholar
  38. Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC.2005; 23(Suppl 16): Abstract 3023.
    Open DOISearch in Google Scholar
  39. Adjei AA, Mandrekar S, Marks RS, Hanson LJ, Aranguren D, Jett JR, Simantov R, B. Schwartz B, Croghan GA. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC).2005; 23(Suppl 16): Abstract 3067.
    Open DOISearch in Google Scholar
  40. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma.2006; 24(Suppl 18): Abstract 7002.
    Open DOISearch in Google Scholar
  41. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.2000; 60(8): 2178-2189.
    Search in Google Scholar
  42. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.2000; 6(3): 957-965.
    Search in Google Scholar
  43. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.2003; 63(21): 7301-7309.
    Search in Google Scholar
  44. Cohen RB, Simon G, Langer CJ, Schol JR, McHale J, Eisenberg P, Hainsworth JD, Liau KF, Healey D. Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC).2004; 22(Suppl 14): Abstract 3014.
    Open DOISearch in Google Scholar
  45. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.2005; 65(10): 4389-4400.
    Open DOISearch in Google Scholar
  46. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer.2003; 4(4): 231-236.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10034-008-0011-3 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Journal RSS Feed
Language: English
Page range: 3 - 10
Published on: May 6, 2009
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Keywords:
Angiogenesis,
Non small cell lung cancer (NSCLC),
Vascular endothelial growth factor (VEGF),
Antiangiogenic agents
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2009 S Metodieva, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons License.

Volume 11 (2008): Issue 2 (December 2008)
Next article